CoChat
Sign Up
Cited by 74Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsNanoparticle-Based Drug Delivery

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Evolving new-age strategies to transport therapeutics across the blood-brain-barrier

Choudhari, Manisha, Hejmady, Siddhanth, Narayan Saha, Ranendra, Damle, Shantanu, Singhvi, Gautam, Alexander, Amit, Kesharwani, Prashant, Kumar Dubey, Sunil·2021·International Journal of Pharmaceutics
DOI 10.1016/j.ijpharm.2021.120351
Open this paper in CoChat — free account

Abstract

A basic understanding of the blood-brain barrier (BBB) is essential for the novel advancements in targeting drugs specific to the brain. Neoplasm compromising the internal structure of BBB that results in impaired vasculature is called as blood tumor barrier (BTB). Besides, the BBB serves as a chief hindrance to the passage of a drug into the brain parenchyma. The small and hydrophilic drugs majorly display an absence of desired molecular characteristics required to cross the BBB. Furthermore, all classes of biologics have failed in the clinical trials of brain diseases over the past years since these biologics are large molecules that do not cross the BBB. Also, new strategies have been discovered that use the Trojan horse technology with the re-engineered biologics for BBB transport. Thus, this review delivers information about the different grades of tumors (I-IV) i.e. examples of BBB/BTB heterogenicity along with the different mechanisms for transporting the therapeutics into the brain tumors by crossing BBB. This review also provides insights into the emerging approaches of peptide delivery and the non-invasive and brain-specific molecular Trojan horse targeting technologies. Also, the several challenges in the clinical development of BBB penetrating IgG fusion protein have been discussed.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ijpharm.2021.120351

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Transport routes of drug molecules across the blood-brain barrier include paracellular and transcellular diffusion, receptor-mediated transcytosis, cell-mediated transcytosis, transporter-mediated transcytosis, and adsorptive mediated transcytosis.

    “Transport routes of the drug molecules across the BBB occurs via the pathways including paracellular and transcellular diffusion, receptor-mediated transcytosis, cell-mediated transcytosis, transporter-mediated transcytosis, and adsorptive mediated transcytosis (Fig. 1a).10”

    From The blood–brain barrier: Structure, regulation and drug delivery (2023) · cites this paper as [10]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 164

  1. Abbott, 2010, Structure and function of the blood–brain barrier, Neurobiol. Disease, 37, 13, 10.1016/j.nbd.2009.07.030 · DOI · Paper page
  2. Agrawal, M., Ajazuddin, Tripathi, D.K., Saraf, S., Saraf, S., Antimisiaris, S.G., Mourtas, S., Hammarlund-Udenaes, M., Alexander, A., 2017a. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease. J. Control Release 260, 61–77. · DOI · Paper page
  3. Agrawal, 2020, Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting, J. Control. Release, 321, 10.1016/j.jconrel.2020.02.020 · DOI
  4. Agrawal, 2017, Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer's disease, J. Control. Release, 260, 61, 10.1016/j.jconrel.2017.05.019 · DOI · Paper page
  5. Ahmed, 1991, Comparative disposition and whole-body autoradiographic distribution of [2-14C] azidothymidine and [2-14C] thymidine in mice, J. Pharmacol. Exp. Ther., 257, 479, 10.1016/S0022-3565(25)24814-5 · DOI
  6. Aird, 1984, A study of intrathecal, cerebrospinal fluid-to-brain exchange, Exp. Neurol., 86, 342, 10.1016/0014-4886(84)90192-4 · DOI
  7. Anderson, 2001, Molecular structure of tight junctions and their role in epithelial transport, Physiology, 16, 126, 10.1152/physiologyonline.2001.16.3.126 · DOI
  8. Arbabi-Ghahroudi, 2017, Camelid single-domain antibodies: historical perspective and future outlook, Front. Immunol., 8, 1589, 10.3389/fimmu.2017.01589 · DOI
  9. Arvanitis, 2020, The blood–brain barrier and blood–tumour barrier in brain tumours and metastases, Nat. Rev. Cancer, 20, 26, 10.1038/s41568-019-0205-x · DOI
  10. Bak, 1999, Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers, Pharm. Res., 16, 24, 10.1023/A:1018854308829 · DOI
  11. Ballabh, 2004, The blood-brain barrier: an overview: structure, regulation, and clinical implications, Neurobiol. Disease, 16, 1, 10.1016/j.nbd.2003.12.016 · DOI
  12. Barnabas, 2019, Drug targeting strategies into the brain for treating neurological diseases, J. Neurosci. Methods, 311, 133, 10.1016/j.jneumeth.2018.10.015 · DOI · Paper page
  13. Begley, D.J., Brightman, M.W., 2003. Structural and functional aspects of the blood-brain barrier, Peptide transport and delivery into the central nervous system. Springer, pp. 39–78. · DOI
  14. Benrabh, 1995, Taurine transport at the blood-brain barrier: an in vivo brain perfusion study, Brain Res., 692, 57, 10.1016/0006-8993(95)00648-A · DOI
  15. Bickel, 1993, Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery, PNAS, 90, 2618, 10.1073/pnas.90.7.2618 · DOI
  16. Billiau, 1981, Tissue distribution of human interferons after exogenous administration in rabbits, monkeys, and mice, Arch. Virol., 68, 19, 10.1007/BF01315163 · DOI
  17. Boado, 2010, Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular trojan horse, J. Pharmacol. Exp. Ther., 333, 961, 10.1124/jpet.109.165092 · DOI
  18. Boado, 2010, Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein, J. Biotechnol., 146, 84, 10.1016/j.jbiotec.2010.01.011 · DOI
  19. Boado, 2013, IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys, Bioconjug. Chem., 24, 97, 10.1021/bc3005123 · DOI
  20. Boado, 2011, CHO cell expression, long-term stability, and primate pharmacokinetics and brain uptake of an IgG–paroxonase-1 fusion protein, Biotechnol. Bioeng., 108, 186, 10.1002/bit.22907 · DOI
  21. Boado, 2016, Insulin receptor antibody− α-N-Acetylglucosaminidase fusion protein penetrates the primate blood–brain barrier and reduces Glycosoaminoglycans in Sanfilippo type B fibroblasts, Mol. Pharm., 13, 1385, 10.1021/acs.molpharmaceut.6b00037 · DOI
  22. Boado, 2016, Insulin receptor antibody-alpha-N-acetylglucosaminidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in sanfilippo type B fibroblasts, Mol. Pharm., 13, 1385, 10.1021/acs.molpharmaceut.6b00037 · DOI
  23. Boado, 2013, Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor, Biotechnol. Bioeng., 110, 1456, 10.1002/bit.24795 · DOI
  24. Boado, 2011, The trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier, J. Drug Del., 2011, 296151
  25. Bockenhoff, 2014, Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A, J. Neurosci.: Off. J. Soc. Neurosci., 34, 3122, 10.1523/JNEUROSCI.4785-13.2014 · DOI
  26. Boesch, 2014, Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia, Mov. Disord., 29, 935, 10.1002/mds.25836 · DOI
  27. Bourassa, P., Alata, W., Tremblay, C., Paris-Robidas, S., Calon, F., 2019. transferrin receptor-mediated uptake at the blood-brain barrier is not impaired by Alzheimer's disease neuropathology. 16, 583–594. · DOI
  28. Burkhart, A., 2014. The Blood-Brain Barrier in vitro Using Primary Culture: Implications for Studies of Therapeutic Gene Expression and Iron Transport. · DOI
  29. Cerrato, C.P., Lehto, T., Langel, Ü., 2014. Peptide-based vectors: recent developments. Biomolecular Concepts 5, 479–488. · DOI
  30. Chesler, 2003, Regulation and modulation of pH in the brain, Physiol. Rev., 83, 1183, 10.1152/physrev.00010.2003 · DOI
  31. Chikhale, 1995, The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism, J. Pharmacol. Exp. Ther., 273, 298, 10.1016/S0022-3565(25)09541-2 · DOI
  32. Chikhale, 1994, Hydrogen bonding potential as a determinant of the in vitro and in situ blood–brain barrier permeability of peptides, Pharm. Res., 11, 412, 10.1023/A:1018969222130 · DOI
  33. Cong, 2015, Ion transporters in brain tumors, Curr. Med. Chem., 22, 1171, 10.2174/0929867322666150114151946 · DOI
  34. Copeland, 2020, Leveraging the dynamic blood–brain barrier for central nervous system nanoparticle-based drug delivery applications, Curr. Opin. Biomed. Eng., 14, 1, 10.1016/j.cobme.2020.04.001 · DOI
  35. Delsing, 2020, Models of the blood-brain barrier using iPSC-derived cells, Mol. Cell. Neurosci., 107, 103533, 10.1016/j.mcn.2020.103533 · DOI
  36. Demeule, 2002, High transcytosis of melanotransferrin (P97) across the blood-brain barrier, J. Neurochem., 83, 924, 10.1046/j.1471-4159.2002.01201.x · DOI
  37. Descamps, 1996, Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells, Am. J. Physiol., 270, H1149
  38. Dubey, 2020, Insulin mediated novel therapies for the treatment of Alzheimer's disease, Life Sci., 117540
  39. Dubey, 2019, Recent expansions on cellular models to uncover the scientific barriers towards drug development for alzheimer’s disease, Cell. Mol. Neurobiol., 39, 181, 10.1007/s10571-019-00653-z · DOI
  40. Dubey, 2018, Herbal medicines in neurodegenerative disorders: an evolutionary approach through novel drug delivery system, J. Environ. Pathol., Toxicol. Oncol. :Off. Organ Int. Soc. Environ. Toxicol. Can., 37, 199, 10.1615/JEnvironPatholToxicolOncol.2018027246 · DOI
  41. Farrington, 2014, A novel platform for engineering blood-brain barrier-crossing bispecific biologics, FASEB J.: Off. Publication Federation Am. Soc. Exp. Biol., 28, 4764, 10.1096/fj.14-253369 · DOI
  42. Foroutan, 2005, Moderate-to-severe ischemic conditions increase activity and phosphorylation of the cerebral microvascular endothelial cell Na+-K+-Cl- cotransporter, Am. J. Physiol. Cell Physiol., 289, C1492, 10.1152/ajpcell.00257.2005 · DOI · Paper page
  43. Fu, 2018, Targeted transport of nanocarriers into brain for theranosis with rabies virus glycoprotein-derived peptide, Mater. Sci. Eng., C, 87, 155, 10.1016/j.msec.2017.12.029 · DOI · Paper page
  44. Gabathuler, 2010, Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases, Neurobiol. Disease, 37, 48, 10.1016/j.nbd.2009.07.028 · DOI
  45. Ghose, 1999, A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases, J. Comb. Chem., 1, 55, 10.1021/cc9800071 · DOI
  46. Graff, 2005, Nasal drug administration: potential for targeted central nervous system delivery, J. Pharm. Sci., 94, 1187, 10.1002/jps.20318 · DOI
  47. Greenwood, 2017, Current research into brain barriers and the delivery of therapeutics for neurological diseases: a report on CNS barrier congress London, UK, 2017, Fluids Barriers CNS, 14, 10.1186/s12987-017-0079-9 · DOI
  48. Gudmundsson, 1999, Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability, Pharm. Res., 16, 7, 10.1023/A:1018828207920 · DOI
  49. Guerrero, 2010, Improving the brain delivery of gold nanoparticles by conjugation with an amphipathic peptide, Nanomedicine, 5, 897, 10.2217/nnm.10.74 · DOI
  50. Halestrap, 2004, The SLC16 gene family—from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond, Pflügers Archiv, 447, 619, 10.1007/s00424-003-1067-2 · DOI
  51. Harilal, 2020, Revisiting the blood-brain barrier: a hard nut to crack in the transportation of drug molecules, Brain Res. Bull., 160, 121, 10.1016/j.brainresbull.2020.03.018 · DOI
  52. Hashimoto, 2020, Tight junction modulation at the blood-brain barrier: current and future perspectives, Biochimica et Biophysica Acta (BBA) - Biomembranes, 1862, 10.1016/j.bbamem.2020.183298 · DOI
  53. Hawkins, 2006, Structure of the blood-brain barrier and its role in the transport of amino acids, J. Nutrit., 136, 218s, 10.1093/jn/136.1.218S · DOI · Paper page
  54. Hervé, 2008, CNS delivery via adsorptive transcytosis, AAPS J., 10, 455, 10.1208/s12248-008-9055-2 · DOI · Paper page
  55. Ho, L., Yemul, S., Knable, L., Katsel, P., Zhao, R., Haroutunian, V., Pasinetti, G.M., 2012b. Insulin Receptor Expression and Activity in the Brains of Nondiabetic Sporadic Alzheimer’s Disease Cases. International Journal of Alzheimer’s Disease 2012, 321280. · DOI · Paper page
  56. Huang, 2020, Blood-brain barrier integrity in the pathogenesis of Alzheimer’s disease, Front. Neuroendocrinol., 59, 100857, 10.1016/j.yfrne.2020.100857 · DOI
  57. Huey, 2017, The potential use of rabies virus glycoprotein-derived peptides to facilitate drug delivery into the central nervous system: a mini review, J. Drug Target., 25, 379, 10.1080/1061186X.2016.1223676 · DOI
  58. Hussain, 1999, The mammalian low-density lipoprotein receptor family, Annu. Rev. Nutr., 19, 141, 10.1146/annurev.nutr.19.1.141 · DOI
  59. Ida, 2011, Primary schwannoma of the bone: a clinicopathologic and radiologic study of 17 cases, Am. J. Surg. Pathol., 35, 989, 10.1097/PAS.0b013e31821fcc0c · DOI
  60. Irudayanathan, 2017, Architecture of the paracellular channels formed by claudins of the blood-brain barrier tight junctions, Ann. N. Y. Acad. Sci., 1405, 131, 10.1111/nyas.13378 · DOI
  61. Johnsen, 2017, Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma, Sci. Rep., 7, 10396, 10.1038/s41598-017-11220-1 · DOI
  62. Kan, 2014, Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB, PNAS, 111, 14870, 10.1073/pnas.1416660111 · DOI
  63. Keep, 2019, The year in review: progress in brain barriers and brain fluid research in 2018, Fluids Barri. CNS, 16, 4, 10.1186/s12987-019-0124-y · DOI
  64. Kido, 2001, Molecular and functional identification of large neutral amino acid transporters LAT1 and LAT2 and their pharmacological relevance at the blood-brain barrier, J. Pharm. Pharmacol., 53, 497, 10.1211/0022357011775794 · DOI
  65. Kleinridders, 2014, Insulin action in brain regulates systemic metabolism and brain function, Diabetes, 63, 2232, 10.2337/db14-0568 · DOI · Paper page
  66. Knowland, 2014, Stepwise recruitment of transcellular and paracellular pathways underlies blood-brain barrier breakdown in stroke, Neuron, 82, 603, 10.1016/j.neuron.2014.03.003 · DOI · Paper page
  67. Krishna, 2018, Pre-clinical pharmacokinetic-pharmacodynamic modelling and biodistribution studies of donepezil hydrochloride by a validated HPLC method, RSC Adv., 8, 24740, 10.1039/C8RA03379J · DOI
  68. Krishna, K.V., Wadhwa, G., Alexander, A., 2019a. Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery. 10, 4124–4135. · DOI
  69. Krishna, 2019, Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery, ACS Chem. Neurosci., 10, 4124, 10.1021/acschemneuro.9b00343 · DOI
  70. Kristensson, 1971, Uptake of exogenous proteins in mouse olfactory cells, Acta Neuropathol., 19, 145, 10.1007/BF00688493 · DOI
  71. Laksitorini, 2014, Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers, Therapeut. Del., 5, 1143, 10.4155/tde.14.67 · DOI
  72. LeBowitz, 2004, Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice, PNAS, 101, 3083, 10.1073/pnas.0308728100 · DOI
  73. Lee, 2000, Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse, J. Pharmacol. Exp. Therap., 292, 1048, 10.1016/S0022-3565(24)35388-1 · DOI
  74. Lee, 2002, Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Aβ peptide radiopharmaceutical, J. Cereb. Blood Flow Metab., 22, 223, 10.1097/00004647-200202000-00010 · DOI
  75. Leoh, 2015, Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1, Mol. Immunol., 67, 407, 10.1016/j.molimm.2015.07.001 · DOI
  76. Levin, 1980, Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability, J. Med. Chem., 23, 682, 10.1021/jm00180a022 · DOI
  77. Li, 2016, Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma, Oncotarget, 7, 79401, 10.18632/oncotarget.12708 · DOI
  78. Lin, 1993, GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons, Science, 260, 1130, 10.1126/science.8493557 · DOI
  79. Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods, 44, 235, 10.1016/S1056-8719(00)00107-6 · DOI
  80. Liu, 2012, Tight junction in blood-brain barrier: an overview of structure, regulation, and regulator substances, CNS Neurosci. Ther., 18, 609, 10.1111/j.1755-5949.2012.00340.x · DOI
  81. Lochhead, 2012, Intranasal delivery of biologics to the central nervous system, Adv. Drug Deliv. Rev., 64, 614, 10.1016/j.addr.2011.11.002 · DOI · Paper page
  82. Loscher, 2005, Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases, Prog. Neurobiol., 76, 22, 10.1016/j.pneurobio.2005.04.006 · DOI
  83. Löscher, 2005, Blood-brain barrier active efflux transporters: ATP-binding cassette gene family, NeuroRx, 2, 86, 10.1602/neurorx.2.1.86 · DOI
  84. Louis, 2016, The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathol., 131, 803, 10.1007/s00401-016-1545-1 · DOI
  85. Lu, 2011, Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein, Biotechnol. Bioeng., 108, 1954, 10.1002/bit.23118 · DOI
  86. Lu, 2012, Adsorptive-mediated brain delivery systems, Curr. Pharm. Biotechnol., 13, 2340, 10.2174/138920112803341851 · DOI
  87. Marrink, 1996, Proton transport across transient single-file water pores in a lipid membrane studied by molecular dynamics simulations, Biophys. J ., 71, 632, 10.1016/S0006-3495(96)79264-0 · DOI
  88. Merkus, 2003, Direct access of drugs to the human brain after intranasal drug administration?, Neurology, 60, 1669, 10.1212/01.WNL.0000067993.60735.77 · DOI · Paper page
  89. Milletti, 2012, Cell-penetrating peptides: classes, origin, and current landscape, Drug Discovery Today, 17, 850, 10.1016/j.drudis.2012.03.002 · DOI
  90. Mokgokong, 2014, Ion transporters in brain endothelial cells that contribute to formation of brain interstitial fluid, Pflügers Arch. Eur. J. Physiol., 466, 887, 10.1007/s00424-013-1342-9 · DOI
  91. Molino, 2017, Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier, FASEB J.: Off. Publicat. Federat. Am. Soc. Exp. Biol., 31, 1807, 10.1096/fj.201600827R · DOI
  92. Moos, 2000, Transferrin and transferrin receptor function in brain barrier systems, Cell. Mol. Neurobiol., 20, 77, 10.1023/A:1006948027674 · DOI
  93. Nagaraja, 2005, In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain, Cerebrospinal Fluid Res., 2, 5, 10.1186/1743-8454-2-5 · DOI
  94. Nassereddine-Sebaei, 1993, Determination of m-nitrophenol and nipecotic acid in mouse tissues by high-performance liquid chromatography after administration of the anticonvulsant m-nitrophenyl-3-piperidinecarboxylate hydrochloride, J. Pharm. Sci., 82, 39, 10.1002/jps.2600820109 · DOI
  95. Nation, D.A., Sweeney, M.D., 2019. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. 25, 270-276. · DOI · Paper page
  96. Nedelkov, 2003, Detection of bound and free IGF-1 and IGF-2 in human plasma via biomolecular interaction analysis mass spectrometry, FEBS Lett., 536, 130, 10.1016/S0014-5793(03)00042-5 · DOI
  97. Neves, A.R., Queiroz, J.F., Lima, S.A.C., 2017. Apo E-Functionalization of Solid Lipid Nanoparticles Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways. 28, 995-1004. · DOI
  98. O'Kane, 1999, Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal, J. Biol. Chem., 274, 31891, 10.1074/jbc.274.45.31891 · DOI · Paper page
  99. O’Donnell, 2010, Chapter 30 - Ion and Water Transport across the Blood-Brain Barrier, 585
  100. O’Kane, 2006, Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+, Am. J. Physiol.-Endocrinol. Metabol., 291, E412, 10.1152/ajpendo.00007.2006 · DOI
  101. Ohtsuki, 2007, Contribution of Carrier-Mediated Transport Systems to the Blood-Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development, Pharm. Res., 24, 1745, 10.1007/s11095-007-9374-5 · DOI
  102. Okuda, 2000, Identification and characterization of the high-affinity choline transporter, Nat. Neurosci., 3, 120, 10.1038/72059 · DOI
  103. Oldendorf, 1972, Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection, Science, 178, 984, 10.1126/science.178.4064.984 · DOI
  104. Pardridge, 2003, Gene Targeting In Vivo with Pegylated Immunoliposomes, Methods Enzymol., 373, 507, 10.1016/S0076-6879(03)73032-8 · DOI
  105. Pardridge, 1998, Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids, Neurochem. Res., 23, 635, 10.1023/A:1022482604276 · DOI
  106. Pardridge, 2003, Blood-brain barrier drug targeting: the future of brain drug development, Mol. Interventions, 3, 151
  107. Pardridge, 2006, Molecular Trojan horses for blood-brain barrier drug delivery, Discovery medicine, 6, 139
  108. Pardridge, 2012, Drug transport across the blood-brain barrier, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 32, 1959, 10.1038/jcbfm.2012.126 · DOI · Paper page
  109. Pardridge, 2012, Drug transport across the blood–brain barrier, J. Cereb. Blood Flow Metab., 32, 1959, 10.1038/jcbfm.2012.126 · DOI · Paper page
  110. Pardridge, 2017, Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology, BioDrugs : Clin. Immunotherapeut. Biopharmaceut. Gene Therapy, 31, 503, 10.1007/s40259-017-0248-z · DOI · Paper page
  111. Pardridge, 2017, Delivery of biologics across the blood–brain barrier with molecular Trojan horse technology, BioDrugs, 31, 503, 10.1007/s40259-017-0248-z · DOI · Paper page
  112. Pardridge, 1991, Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo, J. Pharmacol. Exp. Therapeut., 259, 66, 10.1016/S0022-3565(25)20567-5 · DOI · Paper page
  113. Patel, 2009, Getting into the brain: approaches to enhance brain drug delivery, CNS drugs, 23, 35, 10.2165/0023210-200923010-00003 · DOI
  114. Plum, 2005, The role of insulin receptor signaling in the brain, Trends Endocrinol. Metabol.: TEM, 16, 59, 10.1016/j.tem.2005.01.008 · DOI · Paper page
  115. Pomytkin, I., Costa-Nunes, J.P., 2018. Insulin receptor in the brain: mechanisms of activation and the role in the CNS pathology and treatment. 24, 763–774. · DOI
  116. Pulgar, 2019, Transcytosis to cross the blood brain barrier, new advancements and challenges, Front Neurosci, 12, 10.3389/fnins.2018.01019 · DOI · Paper page
  117. Rahisuddin, 2011, Review on nasal drug delivery system with recent advancement, Int. J. Pharm. Pharm. Sci., 3, 1
  118. Regina, 2008, Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2, Br. J. Pharmacol., 155, 185, 10.1038/bjp.2008.260 · DOI
  119. Regina, 2015, ANG4043, a novel brain-penetrant peptide-mAb conjugate, is efficacious against HER2-positive intracranial tumors in mice, Mol. Can. Ther., 14, 129, 10.1158/1535-7163.MCT-14-0399 · DOI · Paper page
  120. Rudà, R., Trevisan, E., Soffietti, R., 2012. Low-grade gliomas, Handbook of clinical neurology. Elsevier, pp. 437-450. · DOI
  121. Sakaeda, 2000, Enhancement of transport of D-melphalan analogue by conjugation with L-glutamate across bovine brain microvessel endothelial cell monolayers, J. Drug Target., 8, 195, 10.3109/10611860008996865 · DOI
  122. Salvatore, 2006, Point source concentration of GDNF may explain failure of phase II clinical trial, Exp. Neurol., 202, 497, 10.1016/j.expneurol.2006.07.015 · DOI
  123. Sarko, 2010, The pharmacokinetics of cell-penetrating peptides, Mol. Pharm., 7, 2224, 10.1021/mp100223d · DOI
  124. Serlin, Y., Shelef, I., Knyazer, B., Friedman, A., 2015. Anatomy and Physiology of the Blood-Brain Barrier. Seminars in cell & developmental biology 38. · DOI · Paper page
  125. Shan, 2018, Neoplasms of central nervous system: a diagnostic approach, Neoplasm, 1, 10.5772/intechopen.76294 · DOI
  126. Sharma, 2013, Cell penetrating peptide tethered bi-ligand liposomes for delivery to brain in vivo: Biodistribution and transfection, J. Control. Release, 167, 1, 10.1016/j.jconrel.2013.01.016 · DOI
  127. Smith, 2006, Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies, J. Drug Target., 14, 191, 10.1080/10611860600650086 · DOI
  128. Smith, 2005, Carrier-mediated transport to enhance drug delivery to brain, Int. Congr. Ser., 1277, 63, 10.1016/j.ics.2005.02.012 · DOI
  129. Smith, 1986, Cerebrovascular permeability coefficients to sodium, potassium, and chloride, J. Neurochem., 46, 1732, 10.1111/j.1471-4159.1986.tb08491.x · DOI · Paper page
  130. Sood, 2014, Intranasal therapeutic strategies for management of Alzheimer's disease, J. Drug Target., 22, 279, 10.3109/1061186X.2013.876644 · DOI
  131. Stalmans, 2013, Chemical-functional diversity in cell-penetrating peptides, PLoS ONE, 8, e71752, 10.1371/journal.pone.0071752 · DOI
  132. Stella, 2007, Prodrug strategies to overcome poor water solubility, Adv. Drug Deliv. Rev., 59, 677, 10.1016/j.addr.2007.05.013 · DOI
  133. Stoll, 1993, Identification of the cationic amino acid transporter (System y+) of the rat blood-brain barrier, J. Neurochem., 60, 1956, 10.1111/j.1471-4159.1993.tb13428.x · DOI
  134. Strazielle, 2015, Efflux transporters in blood-brain interfaces of the developing brain, Front Neurosci, 9, 10.3389/fnins.2015.00021 · DOI
  135. Suzuki, 2004, Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology, J. Nucl. Med., 45, 1766
  136. Tamai, 1995, Na+-and Cl−-dependent transport of taurine at the blood-brain barrier, Biochem. Pharmacol., 50, 1783, 10.1016/0006-2952(95)02046-2 · DOI
  137. Tao, 2012, Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study, J. Mater. Chem., 22, 11808, 10.1039/c2jm31675g · DOI
  138. Thöle, 2002, Uptake of cationzied albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries, J. Drug Target., 10, 337, 10.1080/10611860290031840 · DOI
  139. Thom, 2019, A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a preclinical model, J. Cereb. Blood Flow Metab., 39, 2074, 10.1177/0271678X18772998 · DOI
  140. Thomas, 2009, Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer, Pharm. Res., 26, 2486, 10.1007/s11095-009-9964-5 · DOI
  141. Thomas, 2009, Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer, Pharm Res, 26, 2486, 10.1007/s11095-009-9964-5 · DOI
  142. Torensma, 2018, The dilemma of cure and damage in oligodendroglioma: ways to tip the balance away from the damage, Cancers, 10, 431, 10.3390/cancers10110431 · DOI
  143. Tsuji, 1999, Tissue selective drug delivery utilizing carrier-mediated transport systems, J. Control. Release, 62, 239, 10.1016/S0168-3659(99)00043-7 · DOI
  144. Tsuji, 2005, Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems, NeuroRx, 2, 54, 10.1602/neurorx.2.1.54 · DOI
  145. Tsuji, 1999, Carrier-mediated or specialized transport of drugs across the blood–brain barrier, Adv. Drug Deliv. Rev., 36, 277, 10.1016/S0169-409X(98)00084-2 · DOI · Paper page
  146. Tuma, 2003, Transcytosis: crossing cellular barriers, Physiol. Rev., 83, 871, 10.1152/physrev.00001.2003 · DOI · Paper page
  147. van de Waterbeemd, 1998, Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors, J. Drug Target., 6, 151, 10.3109/10611869808997889 · DOI
  148. Verrees, 2004, Management of normal pressure hydrocephalus, Am. Fam. Physician, 70, 1071
  149. Vives, 2005, Present and future of cell-penetrating peptide mediated delivery systems: “is the Trojan horse too wild to go only to Troy?”, J Control Release, 109, 77, 10.1016/j.jconrel.2005.09.032 · DOI
  150. Vlieghe, 2010, Peptide-based vectors for blood-brain barrier targeting and delivery of drugs to the central nervous system, Therapeutic Delivery, 1, 489, 10.4155/tde.10.44 · DOI
  151. Wagner, 2012, Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model, PLoS ONE, 7, e32568, 10.1371/journal.pone.0032568 · DOI
  152. Wu, 1996, Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system, J. Pharmacol. Exp. Ther., 279, 77, 10.1016/S0022-3565(25)20939-9 · DOI
  153. Wu, 1999, Neuroprotection with noninvasive neurotrophin delivery to the brain, Proc. Natl. Acad. Sci., 96, 254, 10.1073/pnas.96.1.254 · DOI
  154. Wu, 1997, Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor, J. Clin. Investig., 100, 1804, 10.1172/JCI119708 · DOI
  155. Xiao, 2013, Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics, International Journal of Cell Biology, 2013, 14, 10.1155/2013/703545 · DOI
  156. You, 2018, Targeted Brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in parkinsonian mice, ACS Nano, 12, 4123, 10.1021/acsnano.7b08172 · DOI
  157. Zhang, 2012, Characterization of transferrin receptor-mediated endocytosis and cellular iron delivery of recombinant human serum transferrin from rice (Oryza sativaL.), BMC Biotech., 12, 92, 10.1186/1472-6750-12-92 · DOI
  158. Zhang, 2006, Blood–brain barrier targeting of BDNF improves motor function in rats with middle cerebral artery occlusion, Brain Res., 1111, 227, 10.1016/j.brainres.2006.07.005 · DOI
  159. Zhang, 2004, Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter, Hum. Gene Ther., 15, 339, 10.1089/104303404322959498 · DOI
  160. Zhang, 2008, Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer, Pharm. Res., 25, 400, 10.1007/s11095-007-9357-6 · DOI
  161. Zheng, 2006, Structure and function of the intercellular junctions: barrier of paracellular drug delivery, Curr. Pharm. Des., 12, 2813, 10.2174/138161206777947722 · DOI
  162. Zhou, 2011, Brain-penetrating tumor necrosis factor decoy receptor in the mouse, Drug Metab Dispos, 39, 71, 10.1124/dmd.110.036012 · DOI
  163. Zhu, 2019, Brain drug delivery by adsorption-mediated transcytosis, Brain Targeted Drug Delivery System. Elsevier, 159, 10.1016/B978-0-12-814001-7.00007-X · DOI
  164. Zou, 2013, Cell-penetrating peptide-mediated therapeutic molecule delivery into the central nervous system, Curr. Neuropharmacol., 11, 197, 10.2174/1570159X11311020006 · DOI

Cited by

Sorted by citations

Metadata

Authors
Choudhari, M., Hejmady, S., Narayan Saha, R., Damle, S., Singhvi, G., Alexander, A., Kesharwani, P., & Kumar Dubey, S.
Affiliations
  • Birla Institute of Technology and Science, Pilani (IN)
  • Government of India (IN)
  • Jamia Hamdard (IN)
Corresponding author
Kesharwani, Prashant
ORCID
Venue
International Journal of Pharmaceutics
Publisher
Elsevier BV
Published
2021-04
Volume
599
Pages
120351
ISSN
0378-5173 (ISSN-L)
DOI
10.1016/j.ijpharm.2021.120351
OpenAlex
W3128449039
Cited by
74
References
17
Citations by year
2026: 8 · 2025: 18 · 2024: 17 · 2023: 12 · 2022: 13 · 2021: 6
FWCI
1.40
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • International Journal of Pharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
blood-brain barrier, blood-tumor barrier, brain tumors, peptide delivery, tumor grade, brain drug delivery, biologics
MeSH terms
Antibodies, Monoclonal, Biological Transport, Blood-Brain Barrier, Brain, Drug Delivery Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review